These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23416162)

  • 21. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
    BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells.
    Augello G; Puleio R; Emma MR; Cusimano A; Loria GR; McCubrey JA; Montalto G; Cervello M
    Cell Cycle; 2016; 15(4):573-83. PubMed ID: 26794644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
    Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
    Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
    Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
    Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
    Zhu B; Wei Y
    Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes.
    Wilhelm F; Kässner F; Schmid G; Kratzsch J; Laner A; Wabitsch M; Körner A; Kiess W; Garten A
    Growth Horm IGF Res; 2015 Jun; 25(3):115-20. PubMed ID: 25900365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipopolysaccharide induces lung fibroblast proliferation through Toll-like receptor 4 signaling and the phosphoinositide3-kinase-Akt pathway.
    He Z; Gao Y; Deng Y; Li W; Chen Y; Xing S; Zhao X; Ding J; Wang X
    PLoS One; 2012; 7(4):e35926. PubMed ID: 22563417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
    Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
    Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-193b-Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells.
    Mazzu YZ; Hu Y; Soni RK; Mojica KM; Qin LX; Agius P; Waxman ZM; Mihailovic A; Socci ND; Hendrickson RC; Tuschl T; Singer S
    Cancer Res; 2017 Nov; 77(21):5728-5740. PubMed ID: 28882999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
    Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
    Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo anti-malignant melanoma activity of Alocasia cucullata via modulation of the phosphatase and tensin homolog/phosphoinositide 3-kinase/AKT pathway.
    Fang M; Zhu D; Luo C; Li C; Zhu C; Ou J; Li H; Zhou Y; Huo C; Liu W; Peng J; Peng Q; Mo Z
    J Ethnopharmacol; 2018 Mar; 213():359-365. PubMed ID: 29180042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
    Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
    Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
    Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
    Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.
    Guo Y; Chang H; Li J; Xu XY; Shen L; Yu ZB; Liu WC
    Apoptosis; 2015 Aug; 20(8):1109-21. PubMed ID: 26002438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism.
    Li B; Zhang J; Su Y; Hou Y; Wang Z; Zhao L; Sun S; Fu H
    Mol Med Rep; 2019 Oct; 20(4):3793-3801. PubMed ID: 31485626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.